In a Tough Year, Viking Global Stages an October Comeback

Three major funds help put the firm in the black, despite a major bet on ravaged health care stocks, including Valeant Pharmaceuticals.

O. Andreas Halvorsen, Viking Global Investors (Bloomberg)

Viking Global Investors posted decent gains across all three of its funds in October.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.